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ゲ科 |科INTRODUC TION
ゲsゲ科|科Gene therapy for haemophi旭ia
Gene therapy (GT) for haemophilia is being evaluated for its potential 
to provide long-term, potentially curative treatment for people with 
haemophilia (PWH) by increasing endogenous clotting factor activity. 
This approach could replace the current standard of care, namely exog-
enous factor replacement that has undergone significant improvements 
over the last few decades but remains suboptimal in terms of preserving 
joint and overall health and is associated with a significant quality of life 
(QoL) burden. While GT has the potential to improve physical health 
and overall QoL, clinical experience is still relatively limited. This article 
provides perspectives from a haemophilia patient advocate, with per-
sonal experience of the disease, as well as physicians involved in clinical 
care regarding where GT might address unmet needs and mitigate the 
disease burden for PWH. It should be noted that due to limitations in 
the available evidence, some of the expert perspectives expressed in 
the manuscript will necessarily reflect personal experience and are yet 
unsupported by published peer-reviewed studies.
ゲsゴ科|科The burden of haemophi旭ia
The introduction of clotting factor therapy in the 1960s and 
1970s transformed life expectancy for severe haemophilia from 
under 30 years to near normal.1 The contamination of clotting 
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Gene therapy has the potential to revolutionise treatment for patients with haemophilia 
and is close to entering clinical practice. While factor concentrates have improved out-
comes, individuals still face a lifetime of injections, pain, progressive joint damage, the 
potential for inhibitor development and impaired quality of life. Recently published stud-
ies	in	adeno､associated	vira旭	ｪAAVｫ	vector､mediated	gene	therapy	have	demonstrated	
improvement in endogenous factor levels over sustained periods, significant reduction 
in annualised bleed rates, lower exogenous factor usage and thus far a positive safety 
profile. In making the shared decision to proceed with gene therapy for haemophilia, 
physicians should make it clear that research is ongoing and that there are remaining 
evidence gaps, such as long-term safety profiles and duration of treatment effect. The 
eligibility criteria for gene therapy trials mean that key patient groups may be excluded, 
eg children/adolescents, those with liver or kidney dysfunction and those with a prior 
history	of	factor	inhibitors	or	pre､existing	neutra旭ising	AAV	antibodiess	Gene	therapy	
offers a life-changing opportunity for patients to reduce their bleeding risk while also re-
ducing or abrogating the need for exogenous factor administration. Given the expand-
ing evidence base, both physicians and patients will need sources of clear and reliable 
information to be able to discuss and judge the risks and benefits of treatment.
K E Y W O R D S
Adeno､associated	virusp	factor	IXp	factor	VIIIp	gene	therapyp	haemophi旭ia
This	is	an	open	access	artic旭e	under	the	terms	of	the	Creative	Commons	Attribution	Licensep	which	permits	usep	distribution	and	reproduction	in	any	mediump	
provided the original work is properly cited.
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ゴ科 |科 科架 MIESBACH ET AL.
factor concentrates (CFCs) prepared from pooled plasma with 
HIV and hepatitis viruses, however, blighted many lives.2 Safety 
improved with the introduction of effective viral inactivation 
measures	 fo旭旭owed	 by	 recombinant	 DNA	 techno旭ogy	 in	 the	
1980s.2,3 Since then, CFCs have evolved with the development 
of extended half-life (EHL) versions that improve the QoL by re-
ducing dosing frequency4,5 and increase protection by enabling 
higher trough levels. Despite this, haemophilia continues to im-
pose multiple complications including joint damage, functional 
impairment, acute and chronic pain, mental health/anxiety is-
sues, reduced QoL, as well as impaired social participation, re-
duced educational attainment and diminished work productivity 
(Table 1).
ゲsザ科|科Unmet needs in haemophi旭ia treatment
The limitations of current options highlight the need for less burden-
some and more cost-effective treatment that limits the longer-term 
complications experienced by PWH (Table 2). Preliminary evidence 
in	haemophi旭ia	A	and	B	indicates	that	GT	may	offer	the	potentia旭	to	
address these limitations.
ゴ科 |科WHAT IS GENE THER APY
GT refers to the treatment of a disease through introducing a func-
tional copy of a disease-causing gene, inactivation of the gene's ef-
fects through addition of novel or modified genes, or editing of a 
host gene to correct a congenital mutation.6 GT strategies that are 
currently approved, or approaching approval, are largely aimed at 
treating diseases that are caused by a defect in a single gene, such as 
haemophilia, lipid disorders, retinal diseases and spinal muscular at-
rophy. The most common way to introduce therapeutic genes is via a 
viral vector. Unlike earlier approaches using adenoviral and retroviral 
vectors which insert the transgene into the genome of the host,7 re-
combinant	adeno､associated	virus	 ｪrAAVｫ	vectors	genera旭旭y	remain	
in the nucleus of the transduced cell in non-integrated episomal 
concatemer	form	ｪvector	DNA	旭inked	head	to	tai旭	in	a	circu旭ar	formｫp	
with	on旭y	 rarep	 random	 integrations	 into	host	DNAs8 This reduces 
the	potentia旭	for	genotoxicity	with	rAAV	vectors	when	compared	to	
insertional vectors. While such rare integrations do not appear to 
have been associated with clinical sequelae in animal models or clini-
cal studies, it should be remembered that the large number of vec-
tor genomes (vg) administered during a typical GT treatment means 
TA B L E  ゲ 科 Burden of haemophilia
Burden Cause
Joint damage Can result in chronic pain, disability and joint deformity at an early age 1,54,55
Poor health-related 
quality of life
Closely linked to the extent of joint damage 54
Functional 
impairment
More likely to suffer from arthropathy/arthritis, more likely to require knee/hip replacement compared with the general 
population.1,56 Poor mobility, self-care issues, and inability to perform usual daily activities 57,58
Social isolation Inability to participate in social or sporting activities 59
Pain Higher pain levels and functional impairment associated with anxiety, depression and unemployment.60,61 Pain/discomfort 
is an area where most individuals report experiencing extreme issues.54 Individuals may experience anger and frustra-





impairments and pain 57,63,64
Unmet need Impact
Treatment convenience Lifetime treatment, frequent injections.65,66 Prophylaxis is time-
consuming, contributing to poor adherence 67
Joint damage despite 
factor prophylaxis
Indicates that prophylaxis is failing to control some subclinical 
bleeding 55,68
Inhibitor development Occurs in approximately one-third of patients with severe hae-
mophi旭ia	A	and	┑ズ鯵	of	those	with	haemophi旭ia	B	and	increases	
treatment cost and morbidity risks 69
High lifetime-treatment 
costs
High factor concentrate costs,1,70-72 means availability of factor 
prophylaxis is limited in many countries
Pain See Table 1
Limits on activity and 
social participation
See Table 1
TA B L E  ゴ 科 Current unmet needs in 
haemophilia treatment
科架 科 | 科ザMIESBACH ET AL.
that there is the potential for a large numbers of random integration 
events.
Safety concerns regarding initial GT studies using insertional 
vectors in the 1990s included the death of a patient following adeno-
viral therapy for ornithine transcarbamylase and multiple leukaemia 
cases following a retroviral therapy for severe combined immuno-
deficiency	and	Wiskott､A旭drich	syndromes9-13	More	 recent旭yp	 rAAV	
vectors have been used most commonly as they effectively trans-
duce target cells but have a lower risk of immunogenicity compared 
with adenoviral vectors and have a low risk of genotoxicity versus 
insertional vectors.14	AAV	is	interna旭ised	into	target	ce旭旭s	by	binding	
to specific cell-surface receptors and is trafficked to the nucleus. In 
the	nuc旭eusp	the	AAV	uncoats	by	re旭easing	vira旭	DNA	from	the	capsid	
and the vector transgene is transcribed and expressed.8
ゴsゲ科|科What evidence supports gene therapy for 
haemophi旭ian
ゴsゲsゲ科|科Efficacy
Several publications have provided in-depth reviews of the efficacy 
and safety of GT in haemophilia,15-17 so only brief coverage of thera-
pies in active development is included here.
Haemophilia A
There	 are	 severa旭	 deve旭opmenta旭	 GT	 tria旭s	 for	 haemophi旭ia	 A	 in-
cluding valoctocogene roxaparvovec (BNM 270, Phase 3) at up to 
6 × 1013 vg/kg, SPK-8011 (Phase 1/2) at up to 2 × 1012	vg｠kgp	BAX	
芦芦芦	ｪPhase	ゲ｠ゴｫ	at	an	unstated	dosep	AAVゴ｠芦､HLP､FVIII､Vザ	ｪPhase	
1) at up to 6 × 1012	vg｠kgp	SB､ズゴズ	ｪAAV､FVIIIp	Phase	ゲ｠ゴｫ	at	an	un-
stated	 dose	 and	 BAYゴズゾゾグゴザ	 ｪAAV､human	 B	 domain､dep旭eted	
FVIII) at an unstated dose.18,19 In a trial of valoctocogene roxaparvo-
vec	ｪAAVズ｠B	domain､dep旭eted	hFVIIIｫ	in	nine	menp	the	seven	partici-
pants in the high dose group (6 × 1013 vg/kg) achieved FVIII values 
above the 5 IU/dL cut-off for mild haemophilia for up to 52 weeks 
(range 19-164 IU/dL at 52 weeks).18 These levels were associated 





one	 with	 旭ong､term	 fo旭旭ow､up	 from	 Phase	 ゲ｠ゴ	 ｪscAAVゴ｠芦､LPゲ､
hFIXcｫp	 and	 one	 in	 ear旭y	 Phase	 ゲ｠ゴ	 ｪFLTゲ芦グaｫ	 that	 are	 starting	 to	




Vector-mediated GT in haemophilia B has demonstrated that it is 
possib旭e	to	convert	patients	with	severe	disease	ｪ┑ゲ鯵	FIX	activityｫ	to	
a	umi旭dv	phenotypep	that	is	endogenous	FIX	旭eve旭s	of	ズ鯵	or	more	with	
vectors	 that	 carry	wi旭d､type	 FIX	 such	 as	 AMT､グ葦グ	 or	 scAAVゴ｠芦､
LPゲ､hFIXc	 ｪTab旭e	ザBｫs20-23	 In	additionp	GT	uti旭ising	wi旭d､type	FIX	 is	
associated with the cessation of factor prophylaxis in most partic-
ipantsp	 the	 reduction	 in	 exogenous	 factor	 usage	 by	 ゼザ鯵､ゾ葦鯵	 and	
a	reduction	 in	annua旭ised	b旭eed	rates	of	between	ゼグ鯵	and	ゾジ鯵	in	
those	groups	who	achieved	mean	FIX	activity	┒ズ鯵s20,23





to	 ┒ジグ鯵	 have	 been	 reported	 a旭ong	with	 reductions	 in	 annua旭ised	
b旭eeds	 and	 exogenous	FIX	use	of	 approximate旭y	 ゾグ鯵	 to	ゲググ鯵s	 In	
addition, these variants may allow a lower dose of GT to be used, 
which may be useful if vector dose is a factor in the development of 
capsid-specific immune responses.
ゴsゲsゴ科|科Safety
The	 safety	 profi旭e	 of	 AAV	 vectors	 ref旭ects	 the	 fact	 they	 are	 re-
旭ated	to	natura旭旭y	occurring	AAVp	which	are	genera旭旭y	non､patho-
genic	 in	 humanss	As	 has	 been	 discussedp	 recombinant	AAV	on旭y	
rare旭y	 integrates	 into	 host	 DNAp8 minimising the potential for 
genotoxicity.7 Based on relatively limited data from 35 partici-
pants, one of the main adverse events that was observed in 17 
of	 ザズ	 participants	 ｪジ芦s葦鯵ｫ	 across	 a旭旭	 tria旭s	 was	 transient	 a旭anine	
aminotransferase	 ｪALTｫ	e旭evations	 ｪTab旭e	ザｫp	which	has	a旭so	been	
observed in previous GT trials utilising intramuscular injection.25 
Whi旭e	ALT	e旭evations	are	not	a	safety	issue	per	sep	as	these	events	
were generally asymptomatic and were treated with a course of 
corticosteroids, in some cases they have been associated with a 
reduction in factor activity (Table 3).18,20-23	However	ALT	e旭eva-




V at 6 × 1011 vg/kg (n = 1 of 1) and 2 × 1012 vg/kg (n = 1 of 2), or 
with valoctocogene roxaparvovec (6 × 1012 to 6 × 1013 vg/kg). To 
dea旭	with	ALT	e旭evationsp	at	旭east	three	tria旭s	inc旭uding	the	va旭oc-
tocogene	roxaparvovec	and	SPK､芦グゲゲ	tria旭s	in	haemophi旭ia	A	and	
the FLT180a trial in haemophilia B have used prophylactic ster-
oid treatment.18,24,27 Other treatment-emergent adverse events 
associated with GT include lethargy/fatigue,18,22 anaemia 21 and 
back pain (Table 3B).18 Long-term safety is uncertain as the length 
of follow-up in published studies is generally from 1 year up to a 
maximum of eight years.28,29 There are, however, positive safety 
reports from longer-term follow-up in animals.30.
ゴsゴ科|科Unmet needs
Recent years have seen a major expansion in treatment options 
with the wider availability of EHL CFCs. EHL factors have allowed 
a greater bleed protection by enabling higher trough levels to be 
achieved and have reduced the frequency of intravenous (IV) in-
































Name/description GO-8 Dose ranging 
study
Dose ranging & 
safety







NCT number NCT03001830 NCT03061201 NCT03370172 NCT03569891 NCT03520712 NCT03392974 NCT03588299 NCT03003533

















18 20 10 9 10 40 18 12
Length of follow-up Up to 15 y Up to 3 y Up to 3 y 1 y Up to 5 y Up to 5 y Up to 5 y 1 y
Design Phase 1 Phase 1/2 Phase 1/2 Phase 1/2 Phase 1/2 Phase 3 Phase 1/2 Phase 1/2
Dose, vg/kg 6 × 1011 
2 × 1012 
6 × 1012
Not stated Not stated 6 × 1012 (Co. 1, n = 1) 
2×1013 (Co. 2, n = 1) 
6 × 1013 (Co. 3, n = 7)
6 × 1013 4 × 1013 Not stated 6 × 1011 (n = 2) 
1 × 1012 (n = 3) 









and 69 IU/dL) 
at 6 weeks, 
n = 3
TBC TBC ┑ゲ	IU｠dL	ｪCos	ゲｫ 
2 IU/dL (Co. 2) 
19-164 IU/dL (Co. 3)




TBC TBC TBC 9 (Co. 1) 
88 (Co. 2) 
99 (Co. 3)
TBC TBC TBC 97
Reduction in annual-
ised	b旭eedsp	鯵
TBC TBC TBC Not reported (Co. 1) 
NAc (Co. 2) 
88 (Co. 3)
TBC TBC TBC 97
Safety
Serious	AEd TBC TBC TBC Progression of chronic 
arthropathy
TBC TBC TBC Grade	ゴ	ALT	e旭eva-
































Treatment､re旭ated	AE No Grade III or 
greater	AEs
TBC TBC ALT	e旭evationsp	
arthralgia, back pain, 
fatigue, productive 
cough
TBC TBC TBC TBC
ALT	e旭evations	旭eading	
to reduction/loss of 
FIX	activity
Elevations in 
2/3, no loss of 
FIX	activity
TBC TBC 1/8 TBC TBC TBC 2/12
Bｫ Haemophi旭ia Br AAV gene therapy with wi旭d､type FIX
 AMT､グ葦グゴグ scAAVゴ｠芦､LPゲ､hFIXc21,22a AskBioググゾ
Study details
Name/description Phase 1/2 Phase 1 Phase 1/2
NCT number NCT02396342 NCT00979238 NCT01687608
Status Activep	not	recruiting Activep	not	recruiting Activep	not	recruiting
Therapy
Vector/transgene AAVズ｠codon､optimised	wi旭d､type	hFIX AAV芦｠codon､optimised	wi旭d､type	hFIX AAV芦｠FIX
Study characteristics
Number of participants 10 14 30
Length of follow-up 1 y (5-year follow-up in progress) Up to 3 y Up to 5 y
Design Phase 1/2 Phase 1 Phase 1/2
Dose, vg/kg 5 × 1012 (Co. 1, n = 5) 
2 × 1013 (Co. 2, n = 5)
2×1011(Co. 1, n = 2) 
6 × 1011 (Co. 2, n = 2) 
2 × 1012 (Co. 3, n = 2)
Not stated
Baseline characteristics
FVIII	and	FIX	activityp	IU｠dL ┑ゴb ┑ゲ └ゴ
Efficacy
Endogenous	FIX	or	FVIII	activity 4.4 IU/dL (Co. 1) 


































Bｫ Haemophi旭ia Br AAV gene therapy with wi旭d､type FIX
 AMT､グ葦グゴグ scAAVゴ｠芦､LPゲ､hFIXc21,22a AskBioググゾ
Safety
Serious	AEd ALT	e旭evation	of	mi旭deseverity (n = 2), self-
limiting fever (n = 1)
No TBC
Treatment､re旭ated	AE ALT	e旭evations	ｪザ｠ゲグｫp	pyrexia	ｪザ｠ゲグｫp	anxi-
ety (2/10), palpitations (1/10), headache 
(1/10), prostatitis (1/10), rash (1/10)
ALT	e旭evations	ｪジ｠葦	in	Cos	ザｫp	旭ethargyp	anaemia TBC
ALT	e旭evations	旭eading	to	reduction｠旭oss	of	FIX	activity 0/3 4/4 TBC
Cｫ Haemophi旭ia Br AAV gene therapy with Padua FIX variant
 SPK､ゾググゲ23 AAVズ､hFIXco､Padua ｪAMT､グ葦ゲｫ75 AAVズ､hFIXco､Padua ｪAMT､グ葦ゲｫ76 FLTゲ芦グa24
Study details
Name/description Phase 1/2a 







NCT number NCT03307980 NCT03489291 NCT03569891 NCT03369444
Status Activep	not	recruiting Recruiting Recruiting Recruiting
Therapy
Vector/transgene AAV｠FIX	Padua	variant AAVズ｠FIX	Padua	variant AAVズ｠FIX	Padua	variant AAV｠FIX	Lys､Arg	change	at	
 position 301 variant
Study characteristics
No. participants 20 3 56 18













Design Phase 2 Phase 3 Phase 3 Phase 1/2
Dose, vg/kg 5 × 1011 2 × 1013 2 × 1013 4.5 × 1011 (n = 2, first enrolled 
patients)
Baseline characteristics
FVIII	and	FIX	activityp	IU｠dL ┑ゴ ┑ゴ ┑ゴ ┑ゲ	or	ゲ､ゴ
Efficacy
Endogenous	FIX	or	FVIII	activity ザザsゼ鯵 ザゲ鯵 TBC ┒ジグ鯵
Reduction	in	annua旭ised	FIX	or	FVIII	
usep	鯵
91-100 TBC TBC 100
Reduction	in	annua旭ised	b旭eedsp	鯵 96 TBC TBC No spontaneous bleeds, 1 trau-
matic bleed
ｪCon抄nuesｫ
TA B L E  ザ 科 (Continued)
科架 科 | 科ゼMIESBACH ET AL.
dependent on regular injections and must always be cognisant of the 
peaks and troughs of their factor levels in relation to their activity. 
It is also clear that the same disparity of access which we have seen 
with standard half-life CFCs continues with EHL factors. The 2018 
European Haemophilia Consortium (EHC) survey of 40 European 
countries,31 identified only 10 countries that always, or sometimes, 
had access to EHL CFCs, and there was practically no access in 
Eastern or Central European countries.
Another	advance	in	treatment	has	been	the	deve旭opment	of	hu-
manised bispecific antibody technology, which by binding to both ac-
tivated	FIX	and	factor	X	can	mimic	the	action	of	FVIII	ｪemicizumabｫs	
Subcutaneous	ｪSCｫ	emicizumab	therapy	for	FVIII	deficiency	with	and	
without	inhibitors	has	been	旭icenced	by	the	FDAp32 which will offer a 
degree of freedom from fluctuating factor levels by conferring a con-
stant level of protection while also removing the burden of IV infu-
sion.33,34 The level of protection conferred appears to be in the range 
which will prevent most bleeds, but does not confer a normal or near-
normal level of protection, so treatment for breakthrough bleeds and 
surgery with FVIII clotting factor will continue to be required.
Expectations of GT have changed significantly over the previous 
five	years	as	we	have	seen	FIX	expression	increase	from	a	modest	
ジsジ鯵､ゼ鯵	in	ear旭y	tria旭s	20-22	to	ザザ鯵	more	recent旭yp23 with the current 
hope being sustained expression of factor level in the normal range. 
For	haemophi旭ia	Ap	the	va旭octocogene	roxaparvovec	from	Biomarin	
has	 demonstrated	 expression	 in	 the	 norma旭	 range	 ｪ┒ズグ	 IU｠dLｫ	 at	
52 weeks in 6 of the seven participants in the highest-dose group 
and monitoring continues to assess the duration of expression.18 
Crucially, normal factor levels should be sufficient to free PWH from 
any requirement for treatment with factor concentrates in all situa-
tions, including surgery.
CoreHEM used a modified Delphi decision-making process with 
a group of 49 experts including PWH, clinicians, researchers, reg-
ulators, health technology assessors, payers and drug developers 
to identify outcomes of most importance to PWH.35 CoreHEM 
identified factor level, duration of expression of factor level, impact 
on chronic pain, healthcare resource utilisation, impact on men-
ta旭	hea旭th	and	frequency	of	b旭eeds	as	 the	key	outcomess	A	 factor	
level in the normal range should transform the QoL of PWH. From 
a patient perspective, the duration of expression should ideally 
be lifelong but, if not, should be sustained over many years. With 
the current technology, re-treatment with the same vector is not 
possible, and in any case the economics of GT may not allow this. 
Chronic pain impacts most PWH due to a combination of target 
joints, pre-existing haemophilic arthropathy and subclinical bleeds. 
Anecdota旭旭yp	 there	 have	 been	 reports	 from	 peop旭e	 treated	 with	
EHL	FIX	or	 SC	 therapy	 for	FVIII	 of	 a	 significant	 decrease	 in	 joint	
aches and pains. This may reflect higher trough levels, especially 
with	EHL	FIXp	or	higher	equiva旭ent	旭eve旭	of	protection	conferred	by	
SC therapy for FVIII leading to a significant decrease in subclinical 
bleeds. Therefore, it will be of great interest to assess the long-term 
impact of GT on acute and chronic pain as well as the arthropathy, 
although, for those who already have end-stage arthropathy, the 














































































































































































































































































































































































































































































































































































































































































































































































































































































芦科 |科 科架 MIESBACH ET AL.
Gene therapy with a factor expression in the normal range would 
free PWH from their mental burden and may lead to a real reduc-
tion in the levels of anxiety and depression.36 With greater levels 
of protection, the frequency of bleeds should decrease even in the 
presence of higher levels of physical activity. Freedom to carry out 
normal everyday activities, taken for granted by those without hae-
mophilia, such as walking, running, cycling, swimming and potentially 
riskier sports participation would all become more attainable.
ザ科 |科HOW TO DISCUSS GENE THER APYr 
PHYSICIAN AND PATIENT PERSPEC TIVES 
ON EFFIC ACY AND SAFET Y
ザsゲ科|科Efficacy
From a physician perspective, it will be key to manage patient expec-
tations of GT, particularly in the early days following treatment. GT 
has demonstrated the ability to convert individuals from a severe to 
mild phenotype in terms of endogenous factor activity; however, 
treated adults are likely to have a legacy of joint damage that may 
increase bleed risk even in the post-GT setting with normal or near-
normal endogenous factor activity. During the initial post-GT period, 
and depending on the attained factor level, physicians should advise 
individuals that GT should not be considered as cured, that they 
may continue to require clinical monitoring despite having mild hae-
mophilia, and that any increase in physical activity should be under-
taken cautiously. In trials to date there have been initial indications 
that the bleed risk diminishes with longer length of follow-up after 
GT,18,20 so it will be of interest to determine whether the presence of 
stable factor levels over the longer term can induce clinical improve-
ments in target joints and therefore reduce bleed risk.15 Changes 
in how individuals manage their haemophilia may cause stress or 
anxietyp	so	emotiona旭	support	may	be	neededs	Another	aspect	that	
should become clearer with increasing experience is whether poten-
tial determinants of responses to GT such as the extent of joint dam-
age, presence of neutralising antibodies, potential markers of the 
likelihood of T-cell-mediated immune responses, or other currently 
unknown prognostic factors can be identified.
Patients are likely to be interested in how long they can expect 
the benefits of GT to persist. Within the limited follow-up of current 
tria旭sp	GT	for	haemophi旭ia	B	has	resu旭ted	in	stab旭e	FIX	expression	for	
up to eight years,28,29 however, the longer-term durability of expres-
sion	remains	to	be	determineds	Given	that	 recombinant	AAV	does	
not generally integrate into host genomes, levels of transduction are 
expected to fall as cells turnover and die.8,37 Under normal condi-
tionsp	most	hepatocytes	are	 in	a	quiescent	state	with	┑ゲ鯵､ゴ鯵	un-
dergoing turnover at any time.38,39 While there is some uncertainty 
due to limited data, each non-resting hepatocyte has an estimated 
lifespan of 200-300 days, so it is likely that the documented sta-
b旭e	FIX	旭eve旭s	ref旭ect	 旭ow	hepatocyte	turnovers29,38 Patients should 
also be made aware of the fact that the apparent lack of clinically 
re旭evant	integration	of	the	AAV	vector	a旭so	means	that	any	benefits	
from GT will not be passed on to children. Therefore, following the 
initial meeting with their physician, individuals should write down 
any questions they have and ensure they are answered. They should 
decide what outcomes they would consider to be acceptable, in 
terms of factor activity, duration of factor expression and the po-
tential level of bleed reduction, while appreciating that there are still 
uncertainties in terms of the level and duration of factor expression. 
Given that GT is still in the investigational stage, however, individu-
als should be prepared for the possibility of a poor outcome (such as 
low expression, no expression or early loss of expression).
From a patient perspective, resource utilisation is important, 
particularly in those countries in which treatment costs are borne by 
the individual or treatment can be refused by health insurance com-
panies. They will reasonably expect the best treatment from their 
providers and strong advocacy from their representative patient or-
ganisations. For healthcare provided by a national health service or 
national insurance model, it is likely that an amortisation payment 
model, in which the initial treatment cost is spread by making pay-
ments over several years, may become the preferred model. This 
would be cost-effective, would not have an enormous budget impact 
in year one and could include an element of risk sharing if the contin-
ued payment was linked to continued factor expression at a defined 
level. It may be the case that GT becomes a more attractive option 
even for developing and emerging countries where the current high-
lifetime costs of CFC treatment are not seen as sustainable.
ザsゴ科|科Safety
GT is a relatively new technology that is starting to enter clinical 
practices	As	 is	c旭ear	 from	the	previous	sectionp	 the	current	c旭inica旭	
evidence for GT in haemophilia reflects limited follow-up in a rela-
tively small number of PWH.18,20-23 Thus, when addressing ques-
tions about GT, physicians should be clear that there are areas of 
uncertainty, such as longer-term efficacy and safety, for which only 
further clinical experience will provide answers.
A	key	worry	is	GT	safetyp	particu旭ar旭y	due	to	the	serious	safety	
concerns in the early trials using integrating vectors.40 The majority 
of	current	tria旭s	use	AAV	vectorsp	which	are	much	旭ess	旭ike旭y	to	inte-
grate into the host genome or cause malignant transformation com-
pared	with	integrating	vectorss	As	discussed	in	the	previous	sectionp	
no	major	safety	issues	with	AAV､mediated	GT	have	been	identifiedp	
although the current follow-up periods are relatively short. The nor-
ma旭	range	of	FIX	and	FVIII	in	peop旭e	without	haemophi旭ia	is	ズグ鯵	to	
ゲズグ鯵	of	norma旭p	howeverp	FIX	va旭ues	┒ゲゴズ鯵	and	FVIII	va旭ues	┒ゲググ鯵	




some participants, which was not associated with thrombotic events 
based on a small number of participants with limited follow-up18; 
however, it makes sense to avoid inducing supraphysiologic levels 
of FVIII.
From	 a	 practica旭	 perspectivep	 vector	 DNA	 is	 detectab旭e	 in	
bodily fluids for variable periods ranging from 2-28 weeks in urine, 
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4-52 weeks in saliva, 4-56 weeks in semen, 16-52 weeks in faeces, 
and	from	ジ	weeks	to	┒ゲ	year	in	b旭oods20 The detection of vector ge-
nome fragments does not indicate infectious risk as the test does not 
distinguish between infectious vector particles, and free, episomal, 
or	 integrated	DNAs	 Important旭yp	 recombinant	AAV	vectors	are	de-
signed so that they are unable to replicate. In non-human primates, 
while vector genome sequences were identified in different cell 
populations and tissues for up to 18 months, infectious vector parti-
cles were rapidly cleared within 72 hours.43 In other animal studies, 
sperm	ce旭旭s	appear	to	be	refractory	to	AAV	transductionp	旭essening	
the risks of vertical transmission.44 However, while the risk of third-
party infection is limited, physicians should recommend barrier con-
traception for up to 12 months as a precaution.
From a patient perspective concerns may include the risk of mu-
tagenesis due to vectors insertional events (Table 4). Other concerns 
may include vector shedding and the risk of infecting family mem-
bers and close contacts. Patients may also be worried about whether 
GT may increase the risk of inhibitor induction. There may also be 
anxiety related to potential trade-offs between increasing the vec-
tor dose, the level of factor activity that can be achieved and safety.
ザsザ科|科Questions regarding tria旭 participation
In terms of the physician perspective, setting patient expectations, 
both for clinical trials and ultimately for gene therapy as an approved 
treatment option for haemophilia, will be important, as some PWH 
will not qualify for treatment. The standard inclusion/exclusion cri-
teria employed in clinical trials to date have limited participation to 
adult patients with severe or moderately severe haemophilia,33,36,37 
with exposure to factor treatment for defined periods of time 
ｪ┕ズグ	days	minimum	in	pub旭ished	tria旭sｫp	and	for	most	 tria旭sp	norma旭	
liver and kidney function including absence of liver fibrosis. Trials 
generally exclude those with inhibitors, which would include approx-
imate旭y	one､third	of	peop旭e	with	haemophi旭ia	As	A旭旭	of	the	pub旭ished	
phase	ゲ｠ゴ	studies	for	haemophi旭ia	A	and	B	exc旭uded	patients	with	
active hepatitis B or C (generally defined as active hepatitis antigen, 
DNA	positivity	or	RNA	vira旭	旭oad	positivityｫ	and	active	HIV	infection	
(generally defined as positive serological test for HIV plus a CD4 T-
ce旭旭	count	of	└ゴググ	per	μL and detectable HIV viral load), although one 
study also excluded patients who were HIV positive.37 To date, all 
trials have also excluded patients with pre-existing antibodies to the 
AAV	serotype	specific	to	each	of	the	investigationa旭	productsq	how-
ever, at least one phase 3 trial for haemophilia B [NCT03569891] has 
lifted that exclusion criterion due to lack of evidence for associated 
reduced efficacy or immune responses due to pre-existing low-titre 
neutra旭ising	antibodies	to	AAVズs45 Exclusion of key populations such 
children and adolescents, women with haemophilia,46 and those 
with a history of inhibitors to factor replacement is consistent across 
Phase 1-3 haemophilia GT trials, but a GT trial in people with hae-
mophi旭ia	A	and	inhibitors	has	been	announceds47 If GT does become 
available in children and adolescents, there may be ethical questions 
in terms of gaining informed consent. There has been an initial re-
port of an adverse event potentially associated with a concomitant 
anti-HIV drug,48 so if these kind of interactions are confirmed, care 
may need to be taken in treating some individuals with GT.
Beyond these factors, there are currently no characteristics that 
can be used to identify those who are likely to respond better or 
worse to GT, although this will likely become clearer as the evidence 
base grows. Importantly, the majority of newly approved treatments 
typically will likely gain indications specific to the populations stud-
ied in the clinical trials; thus, it will be important to set expectations 
for excluded populations on timeline of treatment availability and 
the necessity to gather evidence in these groups once GT becomes 
more established.
For patients who participate in clinical trials, there is a practical 
burden of frequent study visits in the short-term, as well as long-
term (5 years on average) follow-up, which may be underestimated 
by	potentia旭	participantss	A	typica旭	tria旭	may	require	week旭y	or	up	to	
tri-weekly visits in the first 6 months, monthly or quarterly visits up 
to 12 months and quarterly or bi-annual visits for the remaining fol-
low-up despite participants potentially having normal or near-normal 
factor levels. Participants will generally need to record factor use and 
bleeds using an e-diary or similar approach, which will then be re-
viewed at each visit. During visits, body fluid samples will be required 
for vector shedding analysis; blood will be required for determining 
factor	 activityp	 inhibitorsp	 旭iver	 enzymesp	 anti､factor	 antibodiesp	 or	
AAV	antibodies｠neutra旭ising	antibodiesp	inf旭ammatory	markersp	T､ce旭旭	
responses and other trial outcomes. Given that trials usually take place 
in specialist centres, study-related visits will likely involve travel and 
TA B L E  ジ 科 Typical questions PWH may have before deciding to 
enter a GT trial
Question
Which trial should I participate in?
What are the results, if any, from earlier phases of the trial?
What is the reputation of the trial team?
What vector is being used and what is the prevalence of pre-existing 
vector antibodies?
Will pre-existing antibodies automatically rule out trial participation 
or have strategies been developed to address this issue?
What vector dose is being infused and what is the anticipated range 
of factor expression? Is a higher vector dose worthwhile if the 
objective is higher factor expression?
Am	I	comfortab旭e	taking	a	prophy旭actic	course	of	steroids	if	that	is	
part of the protocol?
What duration of transgene expression is expected? 
What is the lower limit of duration of expression which would be 
persuasive to you in agreeing to participate in a trial or treatment? 
While lifetime expression is desirable, would I agree to treatment if 
expression was for 10 y? What about 1 y?
What	is	the	potentia旭	for	integration	with	an	AAV	vectorn	What	is	
the likelihood of insertional mutagenesis and the risk of developing 
cancer in the future?
Is there a risk of inhibitor development?
Am	I	comfortab旭e	with	the	degree	of	monitoring	and	commitment	
required, especially in the first year, and with annual follow-up for 
up to 15 y?
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potentially overnight accommodation. Other potential logistical issues 
include limitations on travel, the need for abstinence from alcohol in 
some trials, and potentially limitations on physical exercise to avoid 
muscle-related transaminitis elevations. Even when GT is approved, it 
is likely that treated patients will need additional follow-up to confirm 
sustainable transgene expression, clinical efficacy and safety.
From a patient perspective, with so many trials recruiting and 
ongoing, it is worthwhile to review the key outcomes and the types 
of	questions	PWH	might	have	ｪTab旭e	ジｫs	As	discussed	in	the	previous	
section, key outcomes for PWH include factor level, duration of fac-
tor expression, reduction in chronic pain, healthcare resource utilisa-
tion, impact on mental health and bleed frequency.35 Therefore, it is 
likely that individuals will choose to participate in trials based on the 
factors which are most important to them.
In an ideal scenario, the consent process should involve an in-
dependent person separate from the haemophilia treatment centre 
team who will clearly set out the potential risks to ensure full in-
formed consent; however, this is not a requirement for consent in 
most trials. When introducing trials to PWH, it makes sense for ini-
tial communications to take place in small groups as such meetings 
often develop into discussion forums, which prompts questions that 
some attendees may not have thought about. Individuals should also 
familiarise themselves with relevant information from their national, 
regiona旭	or	g旭oba旭	haemophi旭ia	patient	organisationss	As	GT	becomes	
more established, it will be important for these organisations to pro-
vide patient friendly educational materials including video and to fa-
cilitate education sessions/lectures/conferences for their members. 
PWH should familiarise themselves with the trial protocol.
ザsジ科|科Sources of information on gene therapy
Given the gaps in the evidence base, it will be important to em-
brace a shared decision-making approach.49 Physicians should 
give patients a clear understanding of the benefits and risks of 
GT based on the best available evidence at the time to enable a 
collaborative decision on the best treatment choice based on an 
individual's clinical history, preferences and treatment goals.49	As	
discussed below, patient organisations are also likely to be an im-
portant source of information. Connecting prospective trial par-
ticipants with those who have received GT will also be invaluable, 
particularly in terms of the practicalities of treatment administra-
tion and what to expect following treatment. This peer mentoring 
approach could be facilitated locally on a centre-by-centre basis or 
by patient organisations.
There are currently limited sources of high-quality, indepen-
dent information on GT. The National Hemophilia Foundation 
includes brief patient-focused information on GT (https ://www.
hemop hilia.org/Bleed ing-Disor ders/Future-Thera pies) and details 
a free telephone number that can provide more information on 
novel therapies. The EHC (www.ehc.eu) launched a provider-fo-
cused educational activity in collaboration with Medscape and a 
Novel Products newsletter that will be updated on a regular basis 
which covers GT in some detail.50 The EHC has released a series 
of five educational videos on GT designed for PWH. The World 
Federation of Hemophilia (https ://www.wfh.org) has an online 
video covering several new treatment options including GT ap-
proachess	 The	 American	 Society	 of	 Gene	 and	 Ce旭旭	 Therapy	 has	
two online webinars aimed at PWH, which provide an overview 
of GT in general and the role of GT in haemophilia (https ://www.
asgct.org/meeti ngs-works hops/upcom ing-webin ars/hemop hil-
ia､webinarsｫs	The	Nationa旭	Organization	 for	Rare	Diseases	 ｪhttps	
://rared iseas es.org/rare-disea ses/hemop hilia-b/) has information 
on earlier GT trials.21,22 Therefore, there is a need to provide a 
centralised, accessible and unbiased information source, so that 
PWH can access clear and easy to understand information on the 
novel therapeutic options in haemophilia.
ザsズ科|科The future of haemophi旭ia gene therapy
It is an exciting time in GT, when the long-heralded promise is start-
ing to yield treatments that are entering the clinic. Most ongoing 
haemophilia GT trials utilise the process of gene addition, that is, 
infusing	a	hea旭thy	copy	of	a	c旭otting	 factor	gene	 ｪVIII	or	 IXｫ	via	an	
AAV	vector	into	a	patient	without	a旭tering	their	own	DNAs	There	is	
at least one trial exploring gene editing for haemophilia, a process 
by	which	a	zinc	finger	nuc旭ease	ｪsometimes	referred	to	as	uDNA	scis-
sors) is used to insert the therapeutic transgene into a so-called safe 
harbour or area with high-transcriptional activity.51 Other types of 
GT are also being explored and it will be important for physicians to 
educate patients and families on the different options and discuss 
which approaches meet individual needs. It is likely that when GT ini-
tially become available that they will be prescribed through a limited 
number of expert centres, which should be fully able to discuss and 
educate patients about treatment options.
As	haemophi旭ia	GT	enters	the	c旭inic	and	is	subject	to	survei旭旭ancep	
the longer-term safety and efficacy profiles will become clearer. 
Theoretically, at least, it would make sense to initiate GT before 
joint damage is manifest, which may start between 1 and 2 years of 
age.52 While current trials in haemophilia are confined to adults, as 
the safety profile of GTs becomes more established, it will be im-
portant to include adolescents and children, so that treatments can 
be opened up to this important population. Treatment in younger 
populations, however, may present additional challenges in terms 
of the potential impacts of hormonal and developmental changes as 
well as liver growth on long-term GT effectiveness. The development 
of inhibitors is a major problem that limits clotting factor treatment 
options and efficacy, so it will also be of great interest whether GT, 
either alone or when combined with other approaches such as im-
mune tolerance induction, can benefit such patients, and the future 
resu旭ts	from	the	recent旭y	announced	GT	tria旭	in	haemophi旭ia	A	with	
inhibitors will be awaited with interest.47	A	number	of	different	ap-
proaches have been studied in animals including classical immune 
tolerance induction with repeated exposure to antigens to therapies 
specifically targeting T or B cells.53
While the treatment of haemophilia has improved, it is costly 
and burdensome. Despite CFC, haemophilia still has major adverse 
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impacts on the QoL of PWH including functional impairment, pain, 
and psychosocial issues. Longer-term evidence is needed to confirm 
whether haemophilia GT offers durable efficacy precluding the need 
for factor replacement. Experience from clinical trials so far suggests 
that it offers a life-changing opportunity for PWH to reduce their 
bleeding risk while also reducing or abrogating the need for exoge-
nous factor administration.
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